Kexi Wang

Kexi Wang

Associate

Technology Transactions

Dr. Kexi Wang is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where her practice focuses on technology transactions and corporate law. Prior to attending law school, Kexi conducted doctoral research on the regulatory mechanism of mitosis, where she gained research experience in cell biology, molecular biology, and biochemistry.

Experience

Education

J.D., Harvard Law School, 2019Cum Laude
Ph.D., Biology, University of Toledo, 2014
B.S., Medical Laboratory Tests and Analysis, Shanghai Jiaotong University, School of Medicine, 2009

Admissions

State Bar of California

Credentials

Education

J.D., Harvard Law School, 2019Cum Laude
Ph.D., Biology, University of Toledo, 2014
B.S., Medical Laboratory Tests and Analysis, Shanghai Jiaotong University, School of Medicine, 2009

Admissions

State Bar of California

Recent Insights

Client Highlights

On November 14, 2024, Merck and LaNova Medicines, a privately held clinical-stage biotechnology company, announced that they entered into an exclusive global license for Merck to develop, manufacture, and commercialize LM-299, a novel investigational bispecific antibody targeting both programmed cell death protein-1 (PD-1) and vascular endothelial growth factor (VEGF) that is currently in Phase 1 clinical trials in China. Wilson Sonsini Goodrich & Rosati advised LaNova on the transaction.

Learn More

Client Highlights

On August 22, 2024, Stryker, a global leader in medical technologies, announced a definitive agreement to acquire Vertos Medical Inc., a privately held company providing a minimally invasive solution for treating chronic lower back pain caused by lumbar spinal stenosis. Wilson Sonsini Goodrich & Rosati advised Vertos on the transaction.

Learn More